Catalent Aquires Relthy to Expand South American Business
Catalent has acquired Relthy Laboratorios in Brazil to expand its South American softgel technology business.
Catalent Pharma Solutions has aquired Relthy Laboratórios in Brazil to expand its softgel technology business. The deal follows Catalent’s recent expansion into China, with softgel and clinical trial supply operations.
Catalent acquired 100% of the shares in the Indaiatuba-based, privately held company. Founded in 1988, Relthy produces softgel encapsulated vitamin, mineral and supplement (VMS) products for the Brazilian market, but also supplies products for the prescription and over-the-counter (OTC) segments. Relthy becomes Catalent’s 11th softgel facility adding to its existing pharmaceutical and OTC-focused South American facilities, located in Sorocaba, Brazil, and Buenos Aires, Argentina.
Relthy employs 350 staff and has annual production capacity of approximately 2 billion capsules per annum. The deal further expands Catalent's position into the VMS nutritional market while simultaneously expanding its primary and secondary packaging capabilities in the country. Relthy’s management team will join Catalent.
Source: Catalent Pharma Solutions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
